Histogenics Corp. (NASDAQ:HSGX) had its price objective lowered by stock analysts at Needham & Company LLC from $11.00 to $8.00 in a research report issued on Monday. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 149.22% from the company’s previous close.
A number of other research firms also recently commented on HSGX. William Blair downgraded shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 7th. Zacks Investment Research upgraded shares of Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Friday, August 26th. Finally, BTIG Research upgraded shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price objective for the company in a research note on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $7.05.
Shares of Histogenics Corp. (NASDAQ:HSGX) opened at 3.21 on Monday. The stock has a 50 day moving average price of $2.72 and a 200 day moving average price of $2.27. The company’s market capitalization is $42.60 million. Histogenics Corp. has a 1-year low of $1.39 and a 1-year high of $6.24.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/histogenics-corp-hsgx-pt-lowered-to-8-00-at-needham-company-llc.html
Histogenics Corp. (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.01. During the same period in the prior year, the business posted ($0.58) EPS. Analysts forecast that Histogenics Corp. will post ($2.11) earnings per share for the current year.
A hedge fund recently raised its stake in Histogenics Corp. stock. Sabby Management LLC boosted its stake in shares of Histogenics Corp. (NASDAQ:HSGX) by 28.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,630 shares of the company’s stock after buying an additional 32,965 shares during the period. Sabby Management LLC owned 1.14% of Histogenics Corp. worth $345,000 at the end of the most recent quarter. 38.63% of the stock is currently owned by institutional investors.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Histogenics Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.